Effects of Sintilimab Combined with Chemotherapy on Short-Term Efficacy and Serum CEA,sTim-3 sLAG-3 and T Lymphocyte Subsets in Patients with Advanced Gastric Cancer
Objective:To investigate the effects of Sintilimab combined with chemotherapy on short-term efficacy and serum carcinoembryonic antigen(CEA),immune function,and T lymphocyte subsets in pa-tients with advanced gastric cancer.Methods:A total of 84 patients with advanced gastric cancer treated from May 2020 to May 2022 were randomly divided into an observation group and a control group(42 cases each).The control group received conventional chemotherapy,while the observation group received additional Sintil-imab.Both groups underwent three cycles of continuous treatment(3 months).Clinical outcomes after 1 month of chemotherapy,occurrence of toxicities,and changes in serum tumor markers(CA,CEA,MG-Ag),immune function(sTim-3,sLAG-3),and T lymphocyte subsets(CD3+,CD4+,CD8+)were compared be-tween the two groups before and after 3 cycles of treatment.The 1-year survival rate was recorded during fol-low-up.Results:After 1 month of chemotherapy,the observation group showed a higher clinical effective rate compared to the control group,with no significant differences in toxicities(P>0.05).After 3 cycles of treat-ment,both groups exhibited significant reductions in CA,CEA,MG-Ag,sTim-3,and sLAG-3 levels,and the observation group had lower levels than the control group(all P<0.05),CD3+ and CD4+ levels de-creased,with the observation group higher than the control group,while CD8+ levels increased,and the obser-vation group had lower levels than the control group(all P<0.05).The 1-year survival rate in the observa-tion group was significantly higher than in the control group(P<0.05).Conclusion:Sintilimab combined with chemotherapy demonstrates significant short-term efficacy,high safety,and the ability to improve im-mune function in patients with advanced gastric cancer,thereby alleviating the tumor burden.
万方数据
维普
